Section Arrow
Quote
BEAM.NASDAQ
- Beam Therapeutics
Quotes are at least 15-min delayed:2026/05/20 16:45 EDT
After Hours
Last
 27.11
0 (0.00%)
Bid
27.09
Ask
27.44
High 27.44 
Low 26.8 
Volume 82.44K 
Regular Hours (Closed)
Last
 27.11
+0.78 (+2.96%)
Day High 
27.54 
Prev. Close
26.33 
1-M High
34.375 
Volume 
2.14M 
Bid
27.09
Ask
27.44
Day Low
26.51 
Open
26.64 
1-M Low
25.87 
Market Cap 
2.71B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 30.19 
20-SMA 30 
50-SMA 27.69 
52-W High 36.44 
52-W Low 15.35 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.49/-4.89
Enterprise Value
2.85B
Balance Sheet
Book Value Per Share
11.32
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
63.52M
Operating Revenue Per Share
0.79
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
SLXNSilexion Therapeutics Corp0.5298+0.2608+96.95%-- 
After Hours 0.4854 -0.0444 -8.38%
JUNSJupiter Neurosciences Inc0.205-0.115-35.94%-- 
After Hours 0.215 +0.01 +4.88%
PHGEBiomX Inc.0.5969+0.2229+59.60%-- 
After Hours 0.616 +0.0191 +3.20%
HCWBHCW Biologics Inc2.43+1.37+129.25%-- 
After Hours 2.19 -0.24 -9.88%
MTVAMetaVia Inc.2.89+1.01+53.72%-- 
After Hours 2.77 -0.12 -4.15%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.